Labcorp (LH) to Release Earnings on Tuesday

Labcorp (NYSE:LH) is expected to be issuing its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect the company to announce earnings of $4.12 per share and revenue of $3.5572 billion for the quarter. Labcorp has set its FY 2025 guidance at 16.050-16.500 EPS.Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Tuesday, October 28, 2025 at 9:00 AM ET.

Labcorp (NYSE:LH) last announced its earnings results on Thursday, July 24th. The medical research company reported $4.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.14 by $0.21. Labcorp had a net margin of 5.66% and a return on equity of 15.45%. The firm had revenue of $3.53 billion for the quarter, compared to analyst estimates of $3.49 billion. During the same quarter in the prior year, the business posted $3.94 EPS. The business’s revenue was up 9.6% compared to the same quarter last year. On average, analysts expect Labcorp to post $16 EPS for the current fiscal year and $18 EPS for the next fiscal year.

Labcorp Stock Up 1.9%

Shares of LH opened at $291.34 on Tuesday. The company has a current ratio of 1.50, a quick ratio of 1.32 and a debt-to-equity ratio of 0.61. Labcorp has a 12 month low of $209.38 and a 12 month high of $291.78. The firm’s 50 day moving average is $277.66 and its 200-day moving average is $258.38. The stock has a market capitalization of $24.21 billion, a PE ratio of 32.16, a P/E/G ratio of 1.83 and a beta of 0.89.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 11th. Shareholders of record on Wednesday, November 26th will be paid a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Wednesday, November 26th. Labcorp’s dividend payout ratio (DPR) is 31.79%.

Analysts Set New Price Targets

A number of analysts have recently weighed in on LH shares. Weiss Ratings reiterated a “buy (b-)” rating on shares of Labcorp in a research report on Wednesday, October 8th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Saturday, July 26th. UBS Group increased their price objective on shares of Labcorp from $305.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday. Barclays raised their target price on shares of Labcorp from $275.00 to $290.00 and gave the company an “equal weight” rating in a report on Thursday, October 2nd. Finally, Hsbc Global Res downgraded shares of Labcorp from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 10th. Eleven equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $296.46.

Insider Activity at Labcorp

In related news, Director Kerrii B. Anderson sold 3,500 shares of the stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $280.00, for a total value of $980,000.00. Following the completion of the transaction, the director owned 8,666 shares of the company’s stock, valued at $2,426,480. This represents a 28.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Dwight Gary Gilliland sold 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, July 30th. The shares were sold at an average price of $264.95, for a total transaction of $529,900.00. Following the completion of the sale, the director owned 6,656 shares in the company, valued at $1,763,507.20. This represents a 23.11% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 15,046 shares of company stock valued at $4,074,692 in the last quarter. 0.84% of the stock is owned by company insiders.

Hedge Funds Weigh In On Labcorp

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Headlands Technologies LLC lifted its holdings in shares of Labcorp by 300.0% during the second quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock worth $34,000 after purchasing an additional 96 shares during the period. MUFG Securities EMEA plc bought a new position in Labcorp during the second quarter worth $65,000. Geneos Wealth Management Inc. grew its stake in shares of Labcorp by 61.6% in the 2nd quarter. Geneos Wealth Management Inc. now owns 286 shares of the medical research company’s stock valued at $75,000 after buying an additional 109 shares during the period. B. Riley Wealth Advisors Inc. bought a new position in shares of Labcorp in the 2nd quarter worth $210,000. Finally, Evergreen Capital Management LLC grew its holdings in shares of Labcorp by 8.3% during the second quarter. Evergreen Capital Management LLC now owns 1,193 shares of the medical research company’s stock valued at $313,000 after buying an additional 91 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

About Labcorp

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.